After exiting the FDA less than two weeks ago for unclear reasons, Vinay Prasad is once again director of the Center for ...

The U.S. Preventive Services Task Force makes recommendations for preventive services—including Gilead’s twice-yearly HIV ...

Eli Lilly’s orforglipron cut body weight to a lesser extent than rival Novo Nordisk’s semaglutide, falling into analysts’ ...

Under PreCheck, the FDA will communicate more frequently with pharmaceutical companies, helping them as they establish or ...

The German giant has already trimmed more than 10,000 employees since initiating a massive restructuring initiative in July ...

Strand Therapeutics' lead asset is STX-001, an intra-tumor self-replicating mRNA therapy that carries a payload expressing ...

Higher competition for fewer roles remains the status quo for biopharma professionals, based on BioSpace data. Additionally, ...

Terns, once a rising star in obesity and the MASH space, will refocus on cancer and partner out a handful of obesity assets.

From the price of forthcoming weight loss pill orforglipron, to Most Favored Nation drug pricing and the market battle with ...

From innovation in manufacturing to more-flexible regulation and better communication with payers, much needs to happen to ...

Vertex reported healthy revenue in its second quarter earnings report, though news of VX-993’s mid-stage trial results and ...

Out-licensing drugs to multinational corporations is a natural step for Chinese biotechs, but the recent rise in deals is ...